小剂量盐酸普拉克索治疗帕金森病患者吞咽功能障碍的临床研究  

A Clinical Study of Low-dose Pramipexole for Swallowing Disorders in Patients with Parkinson's Disease

作　　者：王定超[1] 陈文利[1] 李建红[1] 汪子琪[1] 罗会玲[1] 

机构地区：[1]成都市老年病医院神经内科,四川成都611130

出　　处：《中国医药指南》2012年第15期399-400,共2页Guide of China Medicine

基　　金：四川省卫生厅科研课题(编号110098)

摘　　要：目的观察多巴胺受体激动剂盐酸普拉克索治疗帕金森病(PD)患者吞咽功能障碍的疗效和安全性。方法 32例PD伴吞咽功能障碍患者随机分成对照组和普拉克索组。对照组16例继续使用不同剂量的金刚烷胺、多巴丝肼(美多巴);普拉克索组16例在对照组的基础上加用小剂量盐酸普拉克索治疗。两组患者在用药前和用药后第8周均采用藤岛一郎吞咽评分和才藤吞咽障碍分级进行评价。结果普拉克索组PD吞咽功能障碍的藤岛一郎吞咽障碍评分和才藤吞咽障碍分级和对照组比较,差异均有统计学意义(P<0.01)。结论多巴胺受体激动剂盐酸普拉克索治疗帕金森病患者吞咽功能障碍是安全有效的。Objective To evaluate the efficacy and safety of the dopamine agonist pramipexole for swallowing disorders in patients with Parkinson＇s disease（PD）.Methods 32 patients with PD were enrolled in the study and randomly divided into two groups.16 patients in the control group were treated with different doses of amantadine and Duo Basi hydrazine（Madopar）.The patients in the pramipexole group were treated with low dosages of pramipexole based on the control group.Mr Tengdao’s swallowing curative effect evaluation of swallowing and Caiteng’s 7 levels of swallowing barrier were used for observation standard before and 8 weeks after the trial.Results There were significant difference of scores of swallowing curative effect evaluation and levels of swallowing barrier between the control group and ramipexole group（P0.01）.Conclusion Pramipexole is safe and effective in treatment of swallowing disorders in Parkinson＇s disease.

关 键 词：多巴胺激动剂 盐酸普拉克索 帕金森病 吞咽功能障碍 

分 类 号：R742.2[医药卫生—神经病学与精神病学]